Moderna Incorporated said on Thursday that its Covid-19 shot was about 93% effective through six months following the second dose, which shows hardly any change from it’s 94% efficacy reported in the original clinical trial.
However, Moderna still recommends booster shots to be necessary ahead of the winter season as antibody levels decrease. Both Moderna and its rivals Pfizers and BioNTech have been advocating for a third shot to increase their protection against Covid-19 (Reuters).
In regards to vaccine development, Moderna CEO Stephane Bancel said that the company would not produce more than the 800 million to 1 billion doses of the vaccine it has targeted this year. “We are now capacity constrained for 2021, and we are not taking any more orders for 2021 delivery,” he said (Reuters).
“Our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,” Bancel said. The statement comes as public health officials grow concerned about the Delta variant of Covid-19 that has many questioning the efficacy of the vaccine.
ARTICLE: EVA SALGADO
MANAGING EDITOR CARSON CHOATE
PHOTO CREDITS: DECCAN HERALD